Sun Pharma gets Chinese nod for plaque psoriasis injection Tildrakizumab Ruchika Sharma31 May 2023 11:29 AM ISTILUMETRI is a humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23.
Sun Pharma reports 10.5 percent rise in Q2 profit Ruchika Sharma2 Nov 2022 2:30 PM ISTBengaluru: Sun Pharmaceutical Industries Ltd, India's largest drugmaker, on Tuesday reported a surprise 10.5 percent rise in second-quarter profit led...
Sun Pharma net profit up 43 percent at Rs 2,061 crore in Q1 Ruchika Sharma29 July 2022 5:31 PM ISTSpecialty business grew 29 per cent driven by Ilumya, Cequa, Odomzo and Winlevi, he added.
Sun Pharma reports five-year positive results for ILUMYA in Plaque Psoriasis patients Ruchika Sharma2 Nov 2020 1:34 PM ISTILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses.
Sun Pharma Japanese arm unveils Ilumya to treat plaque psoriasis Ruchika Sharma24 Sept 2020 4:45 PM ISTPsoriasis is a chronic immune disease that appears on the skin.
Sun Pharma gets Japanese nod to Plaque Psoriasis drug ILUMYA Ruchika Sharma30 Jun 2020 11:30 AM ISTThe drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle every day with the chronic nature of...
Sun Pharma inks exclusive pact with Hikma to distribute ILUMYA in Middle East, North Africa Ruchika Sharma16 Jun 2020 11:41 AM ISTILUMYAâ„¢ (tildrakizumab) is a USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque...
Sun Pharma announces insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis Farhat Nasim13 Jun 2020 11:54 AM ISTFurthermore, the safety profile of ILUMYA was reconfirmed in a five-year analysis that demonstrated low and similar exposure-adjusted incidence rates...
